RLAY — Relay Therapeutics Share News
0.000.00%
Last trade - 00:00- $3.19bn
- $2.55bn
- $15.36m
Brief: Relay Therapeutics Announces Positive Interim Data For Rly-2608
Relay Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Relay Therapeutics Q2 Net Income USD -92.212 Million
Brief: Relay Therapeutics Says Got Notice Of Termination Of Collaboration & License Agreement, Dated Dec 11, 2020 With Genentech & F. Hoffmann-La Roche
U.S. RESEARCH ROUNDUP-Ciena, Huntsman, Prog Holdings
Brief: Relay Therapeutics Inc - Cash Guidance Remains Unchanged, And Is Expected To Fund Operations Into Second Half Of 2026
Relay Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Relay Therapeutics Q1 Net Income USD -81.387 Million
Relay Therapeutics Inc expected to post a loss of 71 cents a share - Earnings Preview
Relay Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
U.S. STOCKS ON THE MOVE-Core & Main, Commercial Metals, Equifax
U.S. STOCKS ON THE MOVE-Toll Brothers, American Eagle Outfitters, Twilio
U.S. STOCKS ON THE MOVE-Moderna, Coinbase, Ambrx Biopharma
Brief: Relay Therapeutics Announces $30 Mln Private Placement Financing
Relay Therapeutics rises after premium PIPE financing
Relay Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Relay Therapeutics Inc expected to post a loss of 83 cents a share - Earnings Preview
Brief: Relay Therapeutics Announces Initial Rly-4008 (Lirafugratinib) Data Demonstrating Durable Responses Across Multiple Fgfr2-Altered Solid Tumors
Relay Therapeutics Inc reports results for the quarter ended in June - Earnings Summary